Latest Stories

ClinOne CEO promises to radically rethink how clinical trial patient caregivers interact with trials, and plans to compensate them all

DENVER, August 20, 2019 (Businesswire) As a part of ClinOne and our CEO’s personal mission, ClinOne will start compensating/reimbursing caregivers of clinical trial participants for their very significant contribution to research, and the incredible amount of support they commit in supporting patients through clinical trials. “In a personal story, when my dad was diagnosed with […]

ClinOne Makes A Big Push for Clinical Trial Sponsors to Communicate With Their Patients

DENVER, August 13, 2019 (Businesswire)  ClinOne is pushing their sponsors to accelerate the frequency of their communication to clinical trial patients with their new offering. Communication is key to engagement and retention. ClinOne CEO Rob Bohacs states “As a part of every clinical trial journey, patients should receive consistent, relevant information from clinical trial sponsors. […]

MD Referral: How ClinOne Enrolled 400 Patients in Oncology Trial in Just 10 Months

DENVER, August 6, 2019 (Businesswire) When an existing ClinOne client enabled our MD Referral application to support a global phase II study across the United States, Europe and Australia their results far surpassed everyone’s expectations. The sponsor’s aggressive goal to  randomize 400 patients diagnosed with a rare oncology disease within 15 months —  with ClinOne’s […]

Why Registry Clinical Trials Need ClinOne

DENVER, July 30, 2019 (Businesswire) – Given the length of the studies and large numbers of patients in these trials, clinical registries are typically quite costly. ClinOne continues to demonstrate its cost saving efforts through its proven far-reaching solutions.  Patient retention in registry studies proves challenging when there is seemingly limited benefit for patients, as […]

ClinOne and Virtual Clinical Trials: A Natural Fit

DENVER, June 12, 2019 ( – Clinical trials are crucial for new product and device development and are required by the Food and Drug Administration (FDA) before approvals can be granted for their use in the general population. Overall success is dependent on sponsors to supply clinically valid protocols, active participation of engaged sites, and […]